However, myxoid LPS resistant-cells upregulated the expression of HMGA1 and increased NFκB activity after treatment with trabectedin, resulting in tumor progression, but the cells will re-sensitive when drug-resistant cells treat with NF-κB, a NF-κB inhibitor 153. The gene discussed is HMGA1; the disease is neoplasm.